PubMed

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ.

Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.PMID: 16168052 [PubMed - indexed for MEDLINE]Related articlesFree article

PPAR dual agonists: are they opening Pandora's Box?

Balakumar P, Rose M, Ganti SS, Krishan P, Singh M.

Pharmacol Res. 2007 Aug;56(2):91-8. Epub 2007 Mar 14. Review.PMID: 17428674 [PubMed - indexed for MEDLINE]Related articles

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.PMID: 17519293 [PubMed - indexed for MEDLINE]Related articles

PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.

Gross B, Staels B.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):687-710. Review.PMID: 18054742 [PubMed - indexed for MEDLINE]Related articles

Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.

Evans JL, Lin JJ, Goldfine ID.

Curr Diabetes Rev. 2005 Aug;1(3):299-307. Review.PMID: 18220606 [PubMed - indexed for MEDLINE]Related articles

Role of PPAR in cardiovascular diseases.

Das SK, Chakrabarti R.

Recent Pat Cardiovasc Drug Discov. 2006 Jun;1(2):193-209. Review.PMID: 18221086 [PubMed - indexed for MEDLINE]Related articles

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.PMID: 16259526 [PubMed - indexed for MEDLINE]Related articles

Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.

Jay MA, Ren J.

Curr Diabetes Rev. 2007 Feb;3(1):33-9. Review.PMID: 18220654 [PubMed - indexed for MEDLINE]Related articles

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.

Node K, Inoue T, Boyko V, Goldberg I, Fisman EZ, Adler Y, Schwammenthal E, Matas Z, Behar S, Tenenbaum A.

Cardiovasc Diabetol. 2009 Jan 28;8:5.PMID: 19173749 [PubMed - indexed for MEDLINE]Related articlesFree article

[PPAR family and its relationship to metabolic syndrome]

Zhang XY, Chen LH, Guan YF.

Sheng Li Ke Xue Jin Zhan. 2005 Jan;36(1):6-12. Review. Chinese. PMID: 15881336 [PubMed - indexed for MEDLINE]Related articles

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

Fruchart JC, Duriez P.

Drugs Today (Barc). 2006 Jan;42(1):39-64. Review.PMID: 16511610 [PubMed - indexed for MEDLINE]Related articles

Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.

Harrity T, Farrelly D, Tieman A, Chu C, Kunselman L, Gu L, Ponticiello R, Cap M, Qu F, Shao C, Wang W, Zhang H, Fenderson W, Chen S, Devasthale P, Jeon Y, Seethala R, Yang WP, Ren J, Zhou M, Ryono D, Biller S, Mookhtiar KA, Wetterau J, Gregg R, Cheng PT, Hariharan N.

Diabetes. 2006 Jan;55(1):240-8.PMID: 16380499 [PubMed - indexed for MEDLINE]Related articlesFree article

Statins and diabetes.

Carmena R, Betteridge DJ.

Semin Vasc Med. 2004 Nov;4(4):321-32. Review.PMID: 15861314 [PubMed - indexed for MEDLINE]Related articles

Safety issues and prospects for future generations of PPAR modulators.

Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B.

Biochim Biophys Acta. 2007 Aug;1771(8):1065-81. Epub 2007 Feb 24. Review.PMID: 17428730 [PubMed - indexed for MEDLINE]Related articles

Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.

Fernandes-Santos C, Carneiro RE, de Souza Mendonca L, Aguila MB, Mandarim-de-Lacerda CA.

Nutrition. 2009 Jul-Aug;25(7-8):818-27. Epub 2009 Mar 5.PMID: 19268533 [PubMed - indexed for MEDLINE]Related articles

Therapeutic roles of peroxisome proliferator-activated receptor agonists.

Staels B, Fruchart JC.

Diabetes. 2005 Aug;54(8):2460-70. Review.PMID: 16046315 [PubMed - indexed for MEDLINE]Related articlesFree article

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.

Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW.

Endocrinology. 2006 Sep;147(9):4252-62. Epub 2006 May 25.PMID: 16728496 [PubMed - indexed for MEDLINE]Related articlesFree article

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. Review.PMID: 18230960 [PubMed - indexed for MEDLINE]Related articles

Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.

Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.

Am J Ther. 2007 Jan-Feb;14(1):49-62. Review.PMID: 17303976 [PubMed - indexed for MEDLINE]Related articles